INTRODUCTION 1
Breast cancer is the second most common cancer, with 522,000 deaths globally in 2012 and a 2 rising incidence (1) . Surgery is one of the three cornerstones of primary invasive breast cancer 3 treatment, the other two being radiotherapy and systemic therapy. Tumor-free surgical margins 4 are critical in breast conserving surgery (BCS), as local recurrence rates increase with positive 5 resection margins (2-5). Therefore, patients with positive resection margins are often re-operated, 6 causing higher surgical risks, poorer cosmetic results, psychological and physical burden and 7 higher healthcare costs. Currently, pre-operative imaging and tactile information are used during 8 breast surgery to determine the size, localization and extent of the area that has to be removed. 9
However, the efficacy of this approach is poor, with positive margin rates of 20% to 40% being 10 reported worldwide (6) . 11
Molecular imaging is a promising strategy to improve this efficacy; it can be used to 12 visualize and quantify tumor-specific molecular characteristics, and could potentially improve 13 breast cancer care in terms of detection, characterization and surgical and non-surgical 14 management strategies. A potential target for molecular imaging in breast cancer is vascular 15 endothelial growth factor (VEGF)-A, a soluble dimeric glycoprotein that is involved in tumor 16 angiogenesis (7, 8) . VEGF-A is frequently overexpressed in breast cancers with an expression rate 17 of ~73% compared to normal breast tissue (9). It can therefore serve as a more generic tracer 18 target (10-11) without pre-selection of patients compared to other potential targets such as human 19 epidermal growth factor receptor 2 (HER2), which is overexpressed in only 10 to 20% of primary 20 breast cancers (12) (13) (14) . 21
The registered humanized monoclonal antibody bevacizumab not only neutralizes all 1 VEGF-A isoforms, but can also be used as a radiolabeled imaging agent in combination with 2 single photon emission computed tomography (SPECT) and positron emission tomography 3 (PET) (15) . Successful and specific imaging has been performed in patients with melanoma, renal 4 cell cancer, neuroendocrine tumors and breast cancer using 111 In-and 89 Zr-radiolabeled 5 bevacizumab (11, (15) (16) (17) (18) (19) . In these studies, a systemic total microdose of 4.5 mg labeled 6 bevacizumab, i.e. ≤ 30 nmol adhering to the definition of microdosing for proteins according to 7 FDA/EMEA guidelines (20) and as described separately for proteins by Kummar et al (21) , was 8 used which is sub-therapeutic compared to the therapeutic dose of 5-15 mg/kg bodyweight (22-9 24) . In a recent PET imaging study with 89 Zr-bevacizumab in 23 primary breast cancer patients, 10 25 of 26 tumors (96%) were visualized by PET 4 days after 89 Zr-bevacizumab tracer injection 11 with tumor-to-normal tissue ratios of 1.4-10.3 (19). These results prompted us to design an 12 optical imaging study based on the microdosing concept of using a therapeutic antibody as 13 targeting moiety in patients undergoing breast cancer surgery. 14 Recently, optical fluorescence imaging has become suitable for clinical translation due to 15 its favorable characteristics such as absence of ionizing radiation, inherently low-cost technology, 16 and its possibilities for real-time, intra-and post-operative imaging. Two phase I feasibility 17 studies in respectively patients with colorectal cancer imaged with a chimeric fluoresceine 18 demonstrated the feasibility of using the therapeutic monoclonal antibody cetuximab targeting 7
Epidermal Growth Factor Receptor (EGFR), as the targeting moiety of a NIRF tracer in patients 8 with head-and neck cancer (29) . Additionally, the clinical application of a protease-activatable 9 tracer has been reported in patients with soft tissue sarcoma and breast cancer (30). 10
Using bevacizumab conjugated to the NIRF dye IRDye800CW (peak absorption 778 nm, 11 peak emission 795 nm), we decided to determine if this approach could be used for intraoperative 12 guidance in breast cancer surgery, combined with a novel systematic analytic methodology for ex 13 vivo evaluation of tumor-specificity and microdistribution. Bevacizumab-IRDye800CW showed 14 high levels of accumulation in human breast cancer bearing mouse tumors (31), leading to Good 15
Manufacturing Practice (GMP) production of clinical grade bevacizumab-IRDye800CW for 16 human use (32). In conjunction with the progress in the development of NIR intra-operative 17 optical imaging systems for clinical applications, we initiated this first in-human clinical study of 18 clinical grade bevacizumab-IRDye800CW in breast cancer patients. 19
The primary aims of our feasibility study were to provide proof of principle of safety, 20 tumor-specific uptake and tumor margin assessment of the intravenously administered NIRF 21 microdose tracer bevacizumab-IRDye800CW, targeting VEGF-A in patients with primary 22 invasive breast cancer, as validated ex vivo by multiplex advanced pathology imaging. 23
MATERIALS AND METHODS

2
Trial Design 3
The study was a two center, first in human, two-stage, non-randomized, non-blinded, prospective, 4 feasibility study in patients with histologically proven breast cancer scheduled for surgery 5 (registered at www.clinicaltrials.gov, identifier NCT01508572). Primary endpoints were the 6 occurrence of serious adverse events (SAE, adverse events were classified according to the 
Surgical Procedures and Specimen Handling 3
Patients underwent mastectomy or lumpectomy with or without a sentinel lymph node (SLN) 4 procedure or axillary LN dissection, according to standard-of-care procedures and guidelines 5 applicable for breast cancer in The Netherlands (33). During the study period, the positive margin 6 rate for the University Medical Center Groningen was 7.8% and for the University Medical 7
Center it was 5.2%. 8
In short, the SLN procedure was carried out by peri-tumoral injection of Technetium-99m nano-9 colloid followed by lymph scintigraphy after 2-3 hours. During surgery a hand-held gamma 10 counter was used to detect the radioactive signal from the SLN. After the first patient, the 11 protocol was amended to omit patent blue V (Guerbet Asia Pacific) for visualization of the SLN 12 if possible, as this dye interfered with the fluorescent signal after systemic microdosing 4.5 mg 13 bevacizumab-IRDye800CW in this patient during surgery. 14 During surgery, images were recorded at several pre-defined time points during removal 15 of the tumor and SLN with the optical imaging system (for further details see Supplementary 16 Material, section "Optical Imaging System"). A baseline image was recorded before incision of 17 
Follow up 11
Adverse events occurring through approximately 2 weeks after surgery were recorded as 12 spontaneously reported by patients or at an outpatient visit. 13
Ex vivo analyses of tumor samples 14
The following subsections are provided in the Supplementary Material and Methods, section "Ex 14 patients (70%), and HER2 expression scores were negative in 13 patients (65%), 1+ in five 10 patients, 2+ in one patient and 3+ in one patient. In three patients, all the excised tissue was 11 required for standard histological examination due to the small tumor sizes of 6 mm. Two 12 patients (10%) undergoing BCS through a lumpectomy had a positive resection margin on 13 standard histopathological examination, 18 none. 14 No adverse events related to the tracer injection occurred in any of the patients, nor aberrations in 15 hematology or blood chemistry levels. In none of the patients tumor recurrence occurred during 16 follow-up after surgery. 17
Intra-operative Imaging 18
Specimens from two patients were identified with a microscopic irradical resection (i.e. the 19 positive margin) upon histopathological analysis ( Fig. 1 and Supplemental. (Fig. 1K ) and overlay image (Fig.  1   1L) . This confirmed the presence of bevacizumab-IRDye800CW in the tumor area and the 2 designated positive margin in both patients. Supplemental Fig. S1 shows the surgical specimen 3 from the second patient with a positive margin, visualized with our standard operating procedure 4 for ex vivo processing. Fluorescence imaging shows strong signals at the vicinity of the margin in 5 the bread-loaf slices (Fig. S1, panel A) , which was confirmed by NIR optical imaging of paraffin 6 blocks (Fig. S1, panel B , tumor is demarcated by red segmentation), H/E staining (Fig. S1 , panel 7 C), and fluorescence flatbed scanning (Fig. S1 , panel D and E). With one exception, we detected 8 a fluorescent signal in the excised specimens of all patients who were injected with bevacizumab-9
IRDye800CW. In the first patient, a male with breast cancer, in whom we could not detect a 10 fluorescent signal ex vivo, a fluorescent signal prior to incision in the breast was visible but 11 Ex Vivo Processing of Surgical Specimen was applied (Fig. 2) . 23
Bevacizumab-IRDye800CW Blood and Tissue Concentrations 1
The whole blood concentrations of bevacizumab-IRDye800CW decreased during 14 days 2 after injection (Fig. 3A) . The bevacizumab-IRDye800CW concentration in tumor tissue was 3 higher compared to the margin (P < 0.05) or surrounding non-cancerous tissue (P < 0.0001) (Fig.  4   3B ). VEGF-A levels differed between tumor and surrounding tissue (P < 0.001) and between 5 margin and surrounding tissue, (P < 0.05) but not between tumor and margin (not significant) 6 (Fig. 3C) . Bevacizumab-IRDye800CW and VEGF-A concentrations by ELISA correlated in the 7 tumor area (r = 0.63, P = 0.0002) (panel D), but not significantly at the margin or surrounding 8 non-cancerous tissue ( Fig. 3D-F) . Additional SDS-PAGE analysis of tumor lysates of three 9 patients, confirmed the intactness of the bevacizumab-IRDye800CW tracer within the tumor. 10
Fluorescence Imaging and Tumor Margins 11
To compare macroscopic fluorescence imaging with tumor margins, two methods were 12 used: tumor area assessment by defining four tumor margin zones distant from the tumor and by 13 segmentation (Fig. 4) . After flatbed scanning (Fig. 4, panel A) and H/E staining of the paraffin 14 block (Fig. 4, panel D) , four margin zones of 5 x 20 mm were defined (tumor area, 0.5 cm, 1.0 15 cm, 1.5 cm) and scanned (Fig. 4, panel B) , after which the mean fluorescence intensity (MFI) was 16 determined (Fig. 4C) . The MFI of the tumor area differed from the other three tumor margin 17 zones (tumor vs. 0.5 cm, tumor vs. 1.0 cm, tumor vs. 1.5 cm, all P < 0.0001). 18
Similarly, segmentation for separating tumor, stroma and fat was performed on the 19 excised specimen after H/E staining (Fig. 4E, F and G) . Next, the segmented areas were 20 superimposed on the fluorescence flatbed scans (Fig. 4E) , and the MFI was calculated (Fig. 4H) . 21
Tumor segmented areas had a higher MFI compared to stroma (P < 0.0001) and fat (P < 0.0001), 22
which also translated into a significant difference in target-to-background ratios for tumor/stroma 23 versus tumor/fat (P < 0.001) (Supplemental Fig. S2 ). In two patients with a positive margin, themargin was fluorescent, while in the remaining 18 patients with a negative margin there was also 1 no fluorescence in the resection margin. In 90% of all patients there was adjacent / complete 2 overlap of bevacizumab-IRDye800CW and VEGF-A immunohistochemistry staining and in 10% 3 no overlap (Fig. 5) . 4
5
Multiplex Advanced Pathology Imaging (MAPI) 6
For a more detailed analysis of the distribution of bevacizumab-IRDye800CW in tumor tissue, a 7 standardized operating procedure (SOP) for macro-and microscopic mapping was performed at a 8 macroscopic level as depicted in Fig. 2 and at the cellular level in Supplemental Fig. S3 -S5 . 9
H/E staining of 4 μm tissue slides (Fig. S3, panel A and B ) was compared to fluorescence 10 scanning (Fig. S3, panel C and D) . In a superimposed image, both modalities were compared on a 11 macroscopic and microscopic level (Fig. S3 , panel E and F). Fluorescence signal was clearly 12 identified in a tumor sprout surrounded by blood vessels and collagen-rich stroma (rectangle, Fig.  13 S3, panel B, D and F). NIR fluorescence microscopy compared to co-localization of H/E staining 14 for tumor (margin) specificity clearly indicated tumor-specific staining of bevacizumab-15 IRDye800CW (Fig. S3, panel G and H) . 16
For qualitative co-localization of bevacizumab-IRDye800CW with other biomarkers such 17
as VEGF-A expression, CD34 staining for microvessel density and presence of collagen, MAPI 18 was used (Supplemental Movie S1). Fluorescent bevacizumab-IRDye800CW scans were 19 pseudocolored green, whereas hematoxylin-DAB/VEGF-A staining color intensities were color 20 deconvoluted into pseudocolor red and superimposed with the pseudocolor green bevacizumab-21
IRDye800CW scans. 22
Supplemental Fig. S4 shows the co-localization of bevacizumab-IRDye800CW, H/E, 23 VEGF-A, collagen and CD34 in breast cancer and a satellite lesion. A clear co-localization offluorescence intensities as determined by fluorescence imaging (Fig. S4, panel A-D) is present 1 within the tumor area (dotted lines). This was confirmed with H/E staining (Fig. S4, panel E) , 2 segmentation (Fig. S4, panel F) , pseudocolor green bevacizumab-IRDye800CW flatbed scan 3 (Fig. S4, panel G) and superimposed H/E with pseudocolor green (Fig. S4, panel H) . 4
Furthermore, co-localization of fluorescence and VEGF-A staining (Fig. S4, panel I ), collagen 5 (Fig. S4, panel M) and CD34 (Fig. S4, panel Q) could be visualized as such. Additional data is 6 provided for co-localization in ductal carcinoma in situ (DCIS) in Supplemental Fig. S5 . 7
In 18/20 patients, lymph nodes were excised. Only three patients had a tumor positive sentinel 8 lymph node, 13 patients had a negative sentinel lymph node. Two additional patients had lymph 9 nodes with macrometastases: one of them had clinical suspicious macrometastatic lymph nodes, 10 confirmed by ultrasound guided biopsy and axillary lymph node dissection. Only in this patient 11 we could even clearly identify fluorescence activity intraoperatively within the lymph node 12 dissection specimen in situ, confirmed by ex vivo fluorescence and histopathological analysis 13 (Supplemental Fig. S6 ). There was no difference in VEGF-A IHC staining between tumor-14 positive lymph nodes and negative lymph nodes (n=104 lymph node tissue blocks). Co-15 localization of NIR fluorescence showed mainly fluorescence surrounding the tumor cells within 16 a lymph node (Supplemental Fig. S6 ), whereas in a tumor-negative lymph node it was mainly 17 centrally located in the lymph node (Supplemental Fig. S7) . In this first in-human study using a NIRF antibody-based tracer in a microdose regimen, 3 administration of bevacizumab-IRDye800CW was safe with sufficient tumor-specific tracer 4 uptake for margin assessment in primary breast cancer tissue. A novel framework of systematic 5 ex vivo macroscopic imaging and fluorescent image analyses of excised specimen, fresh tissue 6 slices, paraffin blocks and tissue slides showed tumor-specific tracer uptake, thus clearly 7 distinguishing the tumor margins within normal healthy breast tissue. This framework provides a 8 novel tool for evaluation and validation of fluorescent tracers in image-guided surgery. NIR light 9 has low tissue absorption characteristics, mainly caused by hemoglobin, and low 10 autofluorescence properties compared to fluorescent dyes in the visible light (27). In BCS, a 11 negative microscopic resection margin is of great value in order to reduce a re-operation or the 12 risk of recurrent disease (35), even after adjuvant radiotherapy. A NIRF tumor-specific tracer is 13 therefore the most suitable in terms of sensitivity and specificity whether (microscopic) residual 14 tissue is present and should accordingly be excised. 15
Most prior optical imaging efforts in breast cancer patients used the non-targeted NIRF 16
tracer ICG, which binds to plasma proteins. This has been tested extensively for lymphatic 17 mapping in breast cancer (36-40). In breast cancer patients, ICG had SLN identification rates 18 comparable to standard-of-care radiotracers and blue dyes (40). However, ICG is unsuitable due 19 to the limiting formulation and quenching characteristics of the dye for simple and 20 straightforward conjugation to targeting moieties, like antibodies, nanobodies or small peptides. 21
This precludes its use for tumor-specific targeting by NIRF imaging, as in the present study. At targeting, then a subsequent dose-finding or diagnostic accuracy study can be carried out with a 15 higher degree of definitive data. As mentioned by Kummar et al (21), 'microdosing studies are 16 designed with the objective to establish at the very earliest opportunity -before a large numbers 17 of patients have been accrued and exposed to potential drug-associated toxicity -whether an 18 agent is targeting its biological marker in a tumor, and consequently whether further clinical 19 development is warranted' and thus allows selection of tracer candidates more likely to be 20 developed successfully, but also helps in determination of the dosing-scheme for the subsequent 21
Phase II-III clinical studies. 22
Although ex vivo imaging confirmed tumor specific uptake in our study, the absolute 23 fluorescent signal intensities of the targeted tracer were too low to identify tumor margins in situ 24 during actual surgery, for which several explanations are possible. First, the tracer dose used in 1 this study may have been too low to reach the threshold for detecting tumor-specific signal intra-2 operatively originating from microscopic irradical tumor margins. Nevertheless, 90% of all 3 patients using microdosing bevacizumab-IRDye800CW showed adjacent or complete overlap 4 with VEGF-A expression measured by IHC. Second, due to the fact that usually surgical 5 incisions in BCS are small, this might imply that insufficient excitation light reaches the surgical 6 cavity or wound bed or vice versa that emitted NIR light originating from the tracer cannot be 7 collected by the optical imaging system. This might be solved by applying a sterile NIR 8 laparoscope or endoscope close within the wound bed. Third, even with a higher dose, 9 improvements in the sensitivity of the camera system, such as correction algorithms and state-of-10 the-art charge-coupled device (CCD) chips, may be required for intra-operative detection of 11
bevacizumab-IRDye800CW. 12
By increasing the tracer dose to still sub-therapeutic doses, a signal above the threshold of patients with head and neck cancer (HNSCC) up (29) . Similarly, a large clinically proven safe 17 dose range is still available for a bevacizumab NIR tracer. For example, patients treated for 18 colorectal cancer with neo-adjuvant bevacizumab being dosed at 10-15 mg/kg every 3 weeks 19 undergo surgery around 6 weeks after the last bevacizumab dose to avoid wound healing 20 problems. With a half-life of 20 days, the remaining circulating bevacizumab level is around 160 21 mg at that time. This would translate into a minimum 180 mg flat bevacizumab dose, to be 22 injected 3 days before surgery, without increased risk of impaired wound healing. In future 23 studies, we therefore suggest a dose escalation starting around 10 mg and increasing up to the 24 potential maximum of 180 mg. The total costs for microdosing and the procedural costs are 1 estimated to be $1800. As VEGF-A is overexpressed in >70% of all patients with breast cancer 2 eligible for breast conserving surgery, pre-selection by applying a 89 Zr-bevacizumab PET 3 imaging study seems redundant and imposes in ~30% of the patients an increased radiation risk 4 which does not outweigh the risks associated with an injection of a non-radioactive fluorescent 5
tracer. 6
In our clinical study we used the NIR optical imaging system not only during surgery, but 7 also post-operatively during pathological examination to image the complete excised specimen, 
43).
Moreover, the present study has shown that MAPI can be used ex vivo to cross-correlate the 23 fluorescent-labeled therapeutic drug bevacizumab and its tumor-specific targeting and local 1 tumor distribution in humans by using excised specimens. This can be done with both 2 macroscopic and microscopic imaging. This novel co-localization methodology provides a 3 reproducible platform in drug development and subsequent dose-finding studies at the tissue and 4 cellular level for other antibodies (therapeutic or otherwise), nanobodies and small peptides as 5 targeting moiety. 6
As neo-angiogenesis is a universal tumor marker, other tumor types may also benefit from 7 fluorescence imaging using bevacizumab-IRDye800CW. For example, HNSCC, colorectal and 8 esophageal cancer may be suitable for such imaging, as these tumors are located more 9 superficially, leading to higher fluorescence signals and less negative impact on surrounding 10 tissue (i.e. scattering, penetration issues). Currently, three studies are ongoing to determine 11 feasibility of a fluorescent endoscope attached to the camera system after administration of 4.5 12 mg bevacizumab-IRDye800CW intravenously to detect rectal cancer, esophageal cancer and pre-13 malignant and malignant polyps in familial adenomatous polyposis (ClinicalTrials.gov identifiers 14 NCT01972373, NCT02129933 and NCT02113202). This approach is therefore of interest not 15 only for tumor visualization and characterization in intra-operative surgical guidance, but also for 16 diagnostic purposes, drug development and treatment monitoring (42) . 17
In conclusion, this is the first clinical study to demonstrate safety and feasibility of the 18 NIR fluorescent tracer bevacizumab-IRDye800CW for tumor-specific optical imaging in patients 19 with primary breast cancer. Probably, because the administered dose (i.e. microdose of 4.5 mg -20 26 nmol) was low, in situ intra-operative tumor margin detection was not possible. However, 21
immediate NIR optical imaging of the excised specimen in patients with a positive margin 22 imaging purposes, fluorescent intensity values could be optimized using higher tracer doses that 5 are still well below the therapeutic dosing scheme of bevacizumab, such as recently described for 6 cetuximab-IRDye800CW. 7
We have therefore initiated a subsequent phase II dose-finding study to determine the 8 optimal dose for intra-operative use in patients with primary breast cancer 9 (www.clinicaltrials.gov: NCT02583568). 1, 2, or 3) . 
